| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.8 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.0072 | 0.8 |
| mRNA | tubastatin A | GDSC1000 | pan-cancer | AAC | 0.0065 | 0.8 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.0077 | 0.8 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.8 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.0062 | 0.8 |